Rare diseases
Investigational molecules
Locations
70 Rue Balard, 75015 Paris, France
Clinical research in solid tumours spans multiple advanced and metastatic cancer settings, with interest in disease control, tumour response, and treatment options after prior systemic therapy.
Research activity also includes locally advanced and metastatic solid tumour populations, with attention to immunotherapy-exposed disease and treatment-resistant cancer.
Ipsen Pharma runs clinical trials in conditions such as Congenital absence of bile ducts, Neoplasm, Metastatic neoplasm, Neoplasm malignant, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A Study of IPN01203 for Adults With Advanced or Metastatic Solid Tumors After Immune Checkpoint Inhibitor Treatment
FranceA Study of IPN60300 in Adults with Locally Advanced or Metastatic Solid Tumors to Assess Safety, Tolerability and Anti-Cancer Activity
FranceStudy on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia
BelgiumEfficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial
BelgiumComparing Abobotulinumtoxin A and Onabotulinumtoxin A for Adults with Upper Limb Spasticity
FranceStudy on the Safety and Effects of IPN01195 in Adults with Advanced Solid Tumors
FranceStudy of Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Checkpoint Inhibitor Treatment
FranceStudy on Elafibranor for Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid
BelgiumLong-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome
BelgiumStudy of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
